Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 7
2007 2
2008 3
2009 2
2010 4
2011 4
2012 2
2013 1
2015 1
2017 1
2019 1
2020 2
2021 5
2022 3
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience. Le Page E, et al. Among authors: veillard d. Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135706 Free article. Clinical Trial.
COVID-19 Epidemic: Regional Organization Centered on Nursing Homes.
Cofais C, Veillard D, Farges C, Baldeyrou M, Jarno P, Somme D, Corvol A. Cofais C, et al. Among authors: veillard d. J Am Geriatr Soc. 2020 Oct;68(10):2191-2193. doi: 10.1111/jgs.16687. Epub 2020 Aug 3. J Am Geriatr Soc. 2020. PMID: 32557563 Free PMC article. No abstract available.
SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
Lejeune F, Chatton A, Laplaud DA, Le Page E, Wiertlewski S, Edan G, Kerbrat A, Veillard D, Hamonic S, Jousset N, Le Frère F, Ouallet JC, Brochet B, Ruet A, Foucher Y, Michel L. Lejeune F, et al. Among authors: veillard d. J Neurol. 2021 Feb;268(2):669-679. doi: 10.1007/s00415-020-10154-5. Epub 2020 Sep 9. J Neurol. 2021. PMID: 32902734
Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35).
Lamy S, Veillard D, Doyen H, Kerbrat A, Michel L, Chretien E, Ousmen A, Edan G, Le Page E. Lamy S, et al. Among authors: veillard d. Mult Scler Relat Disord. 2023 May;73:104657. doi: 10.1016/j.msard.2023.104657. Epub 2023 Mar 23. Mult Scler Relat Disord. 2023. PMID: 37001411 Free PMC article.
Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
Michel M, Le Page E, Laplaud DA, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Coustans M, Edan G, Chevreul K, Veillard D; West Network for Excellence in Neuroscience; COPOUSEP investigators. Michel M, et al. Among authors: veillard d. Rev Neurol (Paris). 2022 Mar;178(3):241-248. doi: 10.1016/j.neurol.2021.06.009. Epub 2021 Sep 28. Rev Neurol (Paris). 2022. PMID: 34598781 Clinical Trial.
38 results